Dian Diagnostics Group Co., Ltd. (300244.SZ) – Market Overview
- Current price: CNY 22.55
- Trading activity: Flat 0 % during the 24‑hour period ending 10:13 PM Central Europe on 21 Oct 2026.
- Volume: CNY 1.9 bn worth of shares traded, representing 14 % of the daily average.
- Market capitalization: CNY 13.6 bn.
- Shares outstanding: 625 million.
- 52‑week range: Highest CNY 33.3 (14 Jan 2026); lowest CNY 14.48 (16 Dec 2025).
- 200‑day simple moving average (SMA): CNY 18.9.
- Year‑to‑date change: Up 6.66 % since the end of last month.
Recent Financial Performance
Dian Diagnostics reported a significant rebound in profitability for the first nine months of 2026. Key points:
- Net profit increased sharply year‑on‑year, driven largely by a reversal of prior bad‑debt write‑downs and one‑off investment gains.
- Total revenue declined modestly; however, the operating mix shifted toward higher‑margin services and self‑produced diagnostic products.
- Precision‑center network expanded to over 120 sites, and new client additions surpassed 1,200.
- Operating costs were reduced, contributing to improved gross margins.
- Cash‑flow metrics remain strong, and the company has continued to deleverage, lowering its debt ratio.
Market participants responded positively, with strong institutional buying and multiple days of price gains amid broader sector support for medical diagnostics.
Comparative Stock Activity (Past 24 Hours)
| Symbol | Trading change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|
| 002979.SZ (China Leadshine) | 0 % | CNY 51.15 | CNY 16.2 bn | 58.27 |
| 1606.HK (China Development Bank Fin‑h) | –0.98 % | HKD 1.51 | HKD 19.1 bn | 2.93 |
| 1879.HK (Shanghai Xizhi –H) | –6.88 % | HKD 195.6 | HKD 19.1 bn | — |
| 002958.SZ (Qingdao Rural Commercial B) | 0 % | CNY 2.89 | CNY 16.2 bn | 6.54 |
| 688690.SS (Suzhou Nanomicro Technology) | 0 % | CNY 39.8 | CNY 16.2 bn | 86.78 |
Market Context
On 20 Oct 2026, the Shanghai Composite index traded below its six‑month moving average, registering a modest decline with a trading volume exceeding 11 trillion yuan. Among 98 stocks crossing the same reference line, several—such as specialty pharmaceuticals, diagnostic companies, and intelligent manufacturing groups—exhibited notable intraday divergences. The overall market environment reflected a mix of modest gains and adjustments across sectors, with high‑growth areas (e.g., specialty raw‑material production and advanced biotech inputs) exerting upward pressure on related stocks.
Company Profile
Dian Diagnostics Group Co., Ltd. is a third‑party independent medical laboratory operating in China. The company:
- Operates approximately 31 franchised laboratories.
- Serves around 12,000 medical institutions.
- Collaborates with Foundation Medicine, Inc. and F. Hoffmann‑La Roche Ltd. to integrate comprehensive genomic profiling assays into clinical care in mainland China.
- Was founded in 2001 and headquartered in Hangzhou, China.
- Was formerly known as Zhejiang DIAN Diagnostics Co., Ltd. before rebranding in November 2017.
- Is listed on the Shenzhen Stock Exchange (ticker 300244.SZ) with an IPO date of 19 July 2011.
- Maintains an online presence at www.dazd.cn .
